Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia

American Journal of Veterinary Research

Volumn 65, Issue 6, 2004, Pages 761-769

  Tomlinson, Julia E ^a   Wilder, Osbone ^a   Young, Karen M ^a   Blikslager, Anthony T ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTIOFUR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIAZEPAM; ETODOLAC; FLUNIXIN MEGLUMINE; HALOTHANE; ICOSANOID; ISOENZYME; KETAMINE; MANNITOL; OXYGEN; PENTOBARBITAL; SODIUM CHLORIDE; TRITIUM; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; ELECTRIC RESISTANCE; HORSE DISEASE; IMMUNOHISTOCHEMISTRY; INTESTINE ISCHEMIA; INTESTINE MUCOSA PERMEABILITY; INTESTINE VILLUS; JEJUNUM; NEUTROPHIL; NONHUMAN; PERMEABILITY BARRIER; REPERFUSION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CLONIXIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; EICOSANOIDS; ELECTRIC IMPEDANCE; EPITHELIUM; ETODOLAC; GENE EXPRESSION; HISTOLOGICAL TECHNIQUES; HORSE DISEASES; HORSES; ISCHEMIA; ISOENZYMES; JEJUNUM; MANNITOL; NEUTROPHILS; PAIN MEASUREMENT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REPERFUSION; TIME FACTORS; TRITIUM;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 3042571674     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.761     Document Type: Article

References (49)

1. Wineland NPL. National Animal Health Monitoring system. Part I: baseline reference of 1998 equine health management. Washington, DC: USDA, 1998.
2. Traub-Dargatz JL, Kopral CA, Seitzinger AH, et al. Estimate of the national incidence of and operation-level risk factors for colic among horses in the United States, spring 1998 to spring 1999. J Am Vet Med Assoc 2001;219:67-71.
3. Edwards GB, Proudman CJ. An analysis of 75 cases of intestinal obstruction caused by pedunculated lipomas. Equine Vet J 1994;26:18-21.
4. Tinker MK, White NA, Lessard P et al. Prospective study of equine colic incidence and mortality. Equine Vet J 1997;29:448-453.
5. Moore JN, White NA, Berg JN, et al. Endotoxemia following experimental intestinal strangulation obstruction in ponies. Can J Comp Med 1981;45:330-332.
6. Dabareiner RM, White NA, Donaldson LL. Effects of intraluminal distension and decompression on microvascular permeability and hemodynamics of the equine jejunum. Am J Vet Res 2001;62:225-236.
7. Gerard MP, Blikslager AT, Roberts MC, et al. The characteristics of intestinal injury peripheral to strangulating obstruction lesions in the equine small intestine. Equine Vet J 1999;31:331-335.
8. Baskett A, Barton MH, Norton N, et al. Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses. Am J Vet Res 1997;58:1291-1299.
9. Soll A. Pathogenesis of nonsteroidal anti-inflammatory drug-related toxicity. Am J Med 1998;105:10S-15S.
10. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000;119:521-535.
11. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal and inflammatory drugs. N Engl J Med 1999; 340:1888-1899.
12. Meschter CL, Gilbert M, Krook L, et al. The effects of phenylbutazone on the morphology and prostaglandin concentrations of the pyloric mucosa of the equine stomach. Vet Pathol 1990;27:244-253.
13. MacAllister CG, Morgan SJ, Borne AT, et al. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc 1993;202:71-77.
14. Levi S, Goodlad RA, Lee CY, et al. Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet 1990;336:840-843.
15. Rocca B, Fitzgerald GA. Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol 2002;2:603-630.
16. Wallace JL, Bell CJ. Gastromucosal defense. Curr Opin Gastroenterol 1996;12:503-511.
17. Whittle BJR. Mechanisms underlying gastric mucosal damage induced by indomethacin and bile salts, and the actions of prostaglandins. Br J Pharmacol 1977;60:455-460.
18. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-16740.
19. Chandrasekharan NV, Dai H, Turepu Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-13931.
20. Hull MA, Brough JL, Hawkey CJ. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut 1999;45: 529-536.
21. Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66:76-84.
22. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): filling in the gaps toward a Cox continuum? Proc Natl Acad Sci U S A 2002;99:13371-13373.
23. Riendeau D, Percival MD, Brideau C, et al. Etorocoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296: 558-566.
24. Kato M, Nishida S, Kitasato H, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of nonsteroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 2001;53:1679-1685.
25. Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995;281:107-111.
26. Kawai S, Nishida S, Kato M, et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998;347:87-94.
27. Brideau C, Van Staden C, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res 2001;62:1755-1760.
28. Campbell NB, Blikslager AT. The role of cyclooxygenase inhibitors in the repair of ischemic-injured jejunal mucosa in the horse. Equine Vet J Suppl 2000;32:59-64.
29. Cayen MN, Krami M, Ferdinandi ES, et al. The metabolic disposition of etodolac in rats, dogs and man. Drug Metab Rev 1981;12:339-362.
30. Krami M, Cosyns L, Hicks DR, et al. Bioavailability studies with etodolac in dogs and man. Biopharm Drug Dispos 1984;5:63-74.
31. Brocks DR, Jamali F. Etodolac clinical pharmacokinetics. Clin Pharmacokinet 1994;26:259-274.
32. Sellon DC, Roberts MC. Use of butorphanol infusion in horses with colic, in Proceedings. 20th Am Coll Vet Intern Med Forum 2002;220-222.
33. Pritchett LC, Ulibarri C, Roberts MC, et al. Identification of potential physiological and behavioral indicators of postoperative pain in horses after exploratory celiotomy for colic. Appl Anim Behav Sci 2003;80:31-43.
34. Sellon DC, Roberts MC, Blikslager A, et al. Effects of continuous intravenous infusion of butorphanol in horses after exploratory celiotomy, in Proceedings. 7th Int Equine Colic Res Symp 2002;21-23.
35. Giddings RF, Argenzio RA, Stevens CE. Sodium and chloride transport across the equine cecal mucosa. Am J Vet Res 1974;35:1511-1514.
36. Argenzio RA, Leece J, Powell DW Prostanoids inhibit NaCl absorption in experimental porcine cryptosporidiosis. Gastroenterology 1993;104:440-447.
37. Tomlinson J, Blikslager A. Role of nonsteroidal anti-inflammatory drugs in gastrointestinal tract injury and repair. J Am Vet Med Assoc 2003;222:946-951.
38. Sawaoka H, Tsuji S, Tsujii M, et al. Expression of the cyclooxygenase-2 gene in gastric epithelium. J Clin Gastroenterol 1997;25(suppl 1):S105-S110.
39. Mizuno H, Sakamoto C, Matsuda K, et al. induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-397.
40. Higgins AJ, Lees P, Taylor JBO, et al. Flunixin meglumine: quantitative determination in and effects on composition of equine inflammatory exudates. Br Vet J 1986;142:163-169.
41. Gray PA, Warner TD, Vojnovic I, et al. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs. healthy donors. Br J Pharmacol 2002;137:1031-1038.
42. Vogiagis D, Glare EM, Misajon A, et al. Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach, effects of aging and ulcers. Am J Physiol Gastrointest Liver Physiol 2000;278: G820-G827.
43. Schwab JM, Beschorner R, Meyermann R, et al. Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury. J Neurosurg 2002;96:892-899.
44. Blikslager AT, Roberts MC, Argenzio RA. Prostaglandin-induced recovery of barrier function in porcine ileum is triggered by chloride secretion. Am J Physiol Gastrointest Liver Physiol 1999;276: G28-G36.
45. Gookin JL, Galanko JA, Blikslager AT, et al. Prostaglandin-mediated closure of paracellular pathway and not restitution is the primary determinant of barrier recovery in acutely injured porcine ileum. Am J Physiol Gastrointest Liver Physiol 2003;205: G967-G979.
46. Gayle J, Jones SL, Argenzio RA, et al. Neutrophils increase paracellular permeability of restituted ischemic-injured porcine ileum. Surgery 2002;132:461-470.
47. Nilsson UA, Schoenberg MH, Aneman A, et al. Free radicals and pathogenesis during ischemia and reperfusion of the cat small intestine. Gastroenterology 1994;106:629-636.
48. Valle L, Puig M, Pol O. Effects of μ opioid receptor agonists on intestinal secretion and permeability during acute intestinal inflammation in mice. Eur J Pharmacol 2600;389:235-242.
49. Philippe D, Dubuquoy L, Groux H, et al. Anti-inflammatory properties of the μ opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 2003;111:1329-1338.